In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
A deal between J&J and Meiragtx in eye disease shows growing interest from big pharma as gene therapy's commercial issues come into focus.
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…